Turkey Boehringer Ingelheim (BI), the largest private pharma company in the world, has become the latest Big Pharma player to commit to Turkish localization after announcing a contract manufacturing partnership with Abdi Ibrahim, the country’s national pharma champion. The plan is to produce one out of every two boxes of…
China The latest news from Chinese pharma and biotech, including BMS’ attempts to pull out of its Abraxane supply deal with local player BeiGene; a conversation with Qihan Biotech CEO Luhan Yang who is aiming to produce the first pig organs that can be successfully transplanted into humans; and the Republican…
Saudi Arabia Saudi Arabia’s ambitious Vision 2030 economic transformation plan aims at transitioning the Middle East’s largest economy away from an over-reliance on fossil fuels and into a more diversified modern nation. This transition is being felt especially keenly in healthcare, where the Ministry of Health’s functions are shifting with the aim…
Saudi Arabia Prof. Ahmed Aljedai, assistant deputy minister of therapeutic affairs for support services at Saudi Arabia’s Ministry of Health (MoH) outlines how the Saudi healthcare system is being restructured in line with the country’s Vision 2030 economic transformation programme and the three goals of improving access, improving quality, and improving value.…
Pharma Legal Handbook Cannabinoid drugs, medicinal cannabis and opioid drugs in Malaysia – a comprehensive legal overview. Prepared in association with Skrine, a leading law firm in Malaysia, this is an extract from The Pharma Legal Handbook: Malaysia, available to purchase here for GBP 99. CANNABINOID DRUGS 1. Are Cannabinoid Drugs authorized in…
Pharma Legal Handbook An insight into regulatory reforms in Malaysian Pharma. Prepared in association with Skrine, a leading law firm in Malaysia, this is an extract from The Pharma Legal Handbook: Malaysia, available to purchase here for GBP 99. 1. Are there proposals for reform or significant change to the healthcare system? The…
Pharma Legal Handbook The key facts about patents and trademarks in Malaysian Pharma. Prepared in association with Skrine, a leading law firm in Malaysia, this is an extract from The Pharma Legal Handbook: Malaysia, available to purchase here for GBP 99. 1. What are the basic requirements to obtain patent and trademark protection?…
Pharma Legal Handbook All legal aspects surrounding product liability in Malaysian Pharma. Prepared in association with Skrine, a leading law firm in Malaysia, this is an extract from The Pharma Legal Handbook: Malaysia, available to purchase here for GBP 99. 1. What types of liability are recognized in your jurisdiction? Product liability for…
Pharma Legal Handbook A brief overview of the situation regarding traditional medicines and OTC products in Malaysian Pharma. Prepared in association with Skrine, a leading law firm in Malaysia, this is an extract from The Pharma Legal Handbook: Malaysia, available to purchase here for GBP 99. 1. What are the regulatory requirements for…
Pharma Legal Handbook All about marketing, manufacturing, packaging & labeling, advertising in Malaysian Pharma. Prepared in association with Skrine, a leading law firm in Malaysia, this is an extract from The Pharma Legal Handbook: Malaysia, available to purchase here for GBP 99. 1. What is the authorization process for the marketing of new…
India The latest news from Indian pharm and healthcare, including Piramal Enterprises’ decision to demerge and list its pharma arm, the country’s 15 pharma billionaires, Danish CNS firm Lundbeck’s decision to shutter its Indian operations, Bharat Biotech’s connection to the world’s first malaria vaccine, and the two million missing workers within…
Global Carlo Toniatti, chief scientific officer of IRBM, gives his insights into how the increased participation of early-stage ventures in the drug R&D process and the plethora of new research approaches that are recalibrating the role of CROs such as IRBM. An experienced oncologist, Toniatti also weighs in on the key…
See our Cookie Privacy Policy Here